BrainScope

The AI Platform That's Transforming Brain Health

About this Event

BrainScope is a neurotechnology company revolutionizing brain health diagnostics by applying AI to brain electrical activity (EEG). They have developed the first AI/ML-enabled neurology device ever cleared by the FDA and hold a significant first-mover advantage in this space.

BrainScope’s AI-driven platform has led to the development of objective, FDA-cleared biomarkers that enable rapid, radiation-free assessment of neurological conditions, offering a powerful alternative to MRIs and CT scans.

Their commercial device for head injury assessment can be used in the ER to detect bleeding in minutes—cutting patient wait times and reducing unnecessary CT scans by ~50% in major U.S. health systems. This same device also harnesses the power of brain waves to provide the first objective measure of concussion.

Beyond head injury, BrainScope has developed a proof-of-concept biomarker that predicts the earliest onset of Alzheimer’s in individuals with memory complaints, supported by investment from the Alzheimer’s Drug Discovery Foundation. They are in discussions with multiple top-tier brand collaborators to develop a rapid stroke indication. And their biomarkers have the potential to upend CNS drug development, reducing the high costs and failure rates by helping identify the right patients for the right drugs.

With 83 global patents, non-dilutive funding from GE Healthcare, the NFL, and the U.S. Department of Defense, and a pipeline that spans stroke, Alzheimer’s, clinical trial services, and beyond, BrainScope is uniquely positioned in a $21B+ global market.

Register today to watch this online event with BrainScope CEO, Laurie Silver, to hear how the company is redefining how brain health is managed – driving innovation across acute care, drug development, and consumer health.

Video On Demand

– Recorded

July 23

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.